JPI InvestFranΓ§ais
JPI AI Analyst AI assistant Β· JPI Invest
Answers based on the tool's data Β· not financial advice Β· full analysis (free)
All stocks β€Ί Health Care β€Ί EHC

Are analysts right about Encompass Health (EHC)?

Health Care Β· price $120 Β· median target $147 (+23%)
In short β€” Over the past 12 months, 58% of analyst price targets on Encompass Health turned out profitable, for an average return of +16% (across 112 timestamped calls). The current consensus is "Buy" with a median price target of $147 (+23% vs the current $120, from 4 analysts).

πŸ“ˆ See the interactive version (live chart) β†’

πŸ”— Related pages on Encompass Health β€” Financials & fundamentals  Β·  If I had invested  Β·  Dividend
Current price
$120
Median target (12 mo)
$147 +23%
Analyst accuracy (1 yr)
58%
Avg return / call (1 yr)
+16%
πŸ’° Performance & Β« if I invested Β» πŸ“Š Interactive analysis

Historical analyst accuracy

For Encompass Health, we replayed every analyst price target of the past 12 months and measured the real outcome: 58% were profitable, average return +16% (112 calls). At 3 months: +2% average return (35% profitable). The higher the %, the more often analysts were right on this stock.

Most reliable analysts on this stock (past track record)

Their past track record on this stock (targets replayed against real prices) β€” not a forecast of what will happen.

Analyst / brokerCalls i% profitable iAvg return i
Credit Suisse1553%+12%
Raymond James1553%+13%
RBC Capital1369%+22%
Truist Securities1267%+21%
Barclays1173%+20%

Valuation

Is Encompass Health overvalued, and is it a good time to buy Encompass Health right now? If you're wondering, here's a recap to make up your own mind: Encompass Health's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.

The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β€” but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.

MetricEncompass HealthSector median (Health Care)
P/E20.229.4
Forward P/E17.917.1
Net margin10%12%

πŸ‘‰ Encompass Health trades below its sector median (20.2 vs 29.4) β€” potentially undervalued, or lower expected growth.

πŸ“– P/E, PEG, margin…: see the glossary

πŸ’΅ Dividend : Encompass Health pays about $0.93/share/yr β†’ 0.92% yield. what is this?

Frequently asked questions

Is Encompass Health a buy right now?

The analyst consensus on Encompass Health (EHC) is "Buy" (11 bullish, 0 bearish calls over 12 months). This is not advice: historically, 58% of their targets on this stock turned out profitable over 1 year.

What is Encompass Health's price target?

The median 12-month price target is $147 (+23% vs $120), ranging from $140 to $155 (4 analysts).

Are analysts accurate on Encompass Health?

Over 1 year, 58% of analyst targets on Encompass Health were profitable, for an average return of +16% (across 112 timestamped calls). This is JPI Invest's accuracy metric.

What is the Encompass Health stock forecast?

Analysts target a median of $147 within 12 months, i.e. +23% vs the current price. The most bullish targets $155, the most cautious $140.

What is the Encompass Health stock forecast for 2026 or long term (2030)?

Note: analyst targets are 12-month (median $147, +23%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (58%), and the stock's past trajectory.

Is Encompass Health overvalued?

Its P/E is 20.2, forward P/E 17.9. A forward P/E lower than the current P/E means earnings are expected to grow.

πŸ“Š See the full interactive analysis of Encompass Health β†’

What is JPI Invest?

JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β€” on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.

Explore JPI Invest for free β†’ How it works: the method β†’

⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.